Oxford Target Therapeutics Ltd

Oxford Target Therapeutics is a pioneering biotech company based in Oxford, UK, with a core focus on drug discovery for innovative cancer therapies. Our in-house drug discovery capabilities serve as the backbone of our efforts to revolutionize cancer treatment. By leveraging cutting-edge research and scientific advancements, we are dedicated to unearthing novel drug candidates that target the Anaphase-Promoting Complex/Cyclosome (APC/C) pathway, a crucial and unique mechanism involved in cancer progression. OTT has a robust and dynamic drug discovery process in place. This allows us to independently nurture and develop promising drug candidates, from early discovery stages to preclinical and clinical development. We have a clear strategy of focusing on discovering and developing novel oncology drugs and entering into corporate deals with pharma companies for finalising development and commercialisation. OTT has extensive drug discovery IP and capabilities, leveraging our network of collaborators, institutions and experts to advance our drugs to the inflection point. Our company is young, but we have the experience and come from the pharma & biotech industry, science/medicine and finance. We have an entrepreneurial culture and a large network. Our vision is to become a successful biotech company with disruptive treatments to help millions of cancer sufferers around the world, capitalizing on partnerships and delivering value to our shareholders. We value Patient-Centricity, Scientific Excellence, Integrity and Ethics, Collaboration and Partnership, Empowerment and Diversity, Sustainability and Social Responsibility. We believe that success is driven by good people and diversity focusing on talent and experience. We are driven by passion and professionalism.